Ecallantide, as known as Kalbitor, is a drug used for the treatment of hereditary angioedema (HAE) and in the prevention of blood loss in cardiothoracic surgery. It is an inhibitor of the protein kallikrein and a 60-amino acid polypeptide which was developed from a Kunitz domain through phage display to mimic antibodies inhibiting kallikrein. HAE is caused by a mutation of the C1-inhibitor gene. Defective or missing C1-inhibitor permits activation of kallikrein, a protease that is responsible for liberating bradykinin from its precursor kininogen. An excess of bradykinin leads to fluid leakage from blood vessels, causing swelling of tissues typical of HAE. Ecallantide suppresses this pathogenetic mechanism by selectively and reversibly inhibiting the activity of plasma kallikrein.  >> Read More

1. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

2. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

3. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet

4. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

5. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line

Ecallantide (Kalbitor [previously, DX-88]; Dyax, Cambridge, MA) is a recombinant protein synthesized in the yeast Pichia pastoris. Ecallantide is a potent and specific inhibitor of plasma kallikrein. In phase 2 trials, symptoms of angioedema improved within 4 hours after treatment with ecallantide.18,21 The Evaluation of DX-88's Effects in Mitigating Angioedema (EDEMA) 3 trial was a randomized, placebo-controlled, phase 3 evaluation of ecallantide for the treatment of acute attacks of angioedema in patients with hereditary angioedema.

Ecallantide for the Treatment of Acute Attacks in Hereditary Angioedema

Hereditary angioedema (HAE) is a rare, debilitating, and potentially fatal disease characterized by acute attacks of swelling that can affect the abdomen/gastrointestinal tract, larynx, face, genitals, and extremities. Ecallantide is a novel plasma kallikrein inhibitor developed for the treatment of acute HAE attacks. Ecallantide provides relief of acute HAE attack symptoms, with rapidity of response commensurate with therapeutic needs for HAE attack locations.

Response time for ecallantide treatment of acute hereditary angioedema attacks